XML 76 R61.htm IDEA: XBRL DOCUMENT
v3.22.2

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) |  |  |  | 2 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Oct. 01, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) reporting_unit | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) reporting_unit | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) reporting_unit | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($)
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  | $ 14,000,000 | $ 195,000,000 |
Finite-lived intangible assets |  |  |  | $ 4,624,000,000 | $ 4,624,000,000 |  |  | 4,624,000,000 |  | $ 5,250,000,000
Fair value of reporting value, greater than its carrying value |  | 45.00% | 40.00% |  |  |  | 45.00% |  | 45.00% |
Goodwill impairment |  | $ 0 | $ 0 |  |  |  |  | 83,000,000 |  | 469,000,000
Accumulated goodwill impairment charges |  |  |  | 4,263,000,000 | 4,263,000,000 |  |  | 4,263,000,000 |  |
Revenues |  |  |  |  | 1,967,000,000 |  | $ 2,100,000,000 | 3,885,000,000 | $ 4,127,000,000 |
Xifaxan Branded Products |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  |  |  | $ 2,963,000,000 | 2,963,000,000 |  |  | $ 2,963,000,000 |  |
Finite lived intangible assets, useful life |  |  |  |  |  |  |  | 66 months |  |
Finite lived intangible assets, annual amortization expense |  |  |  |  |  |  |  | $ 539,000,000 |  |
Bausch + Lomb |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Number of reporting units | reporting_unit |  |  |  | 3 |  |  |  |  |  |
Ortho Dermatologics |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Goodwill impairment |  |  |  |  |  |  |  | $ 0 |  | 469,000,000
Number of reporting units | reporting_unit |  |  |  |  |  | 2 |  | 2 |  |
Salix |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Goodwill impairment |  |  |  |  |  |  |  | $ 0 |  | 0
Revenues |  |  |  |  | $ 501,000,000 |  | $ 516,000,000 | 965,000,000 | $ 988,000,000 |
Salix | Xifaxan Branded Products |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  | $ 775,000,000 |  |
Salix | Xifaxan Branded Products | Product Concentration Risk | Revenue from Contract with Customer, Segment Benchmark |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  | 81.00% |  |  | 80.00% |  |
Reporting Units Excluding Ortho Dermatologics |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  |  | 0
Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rate | 1.00% |  | 1.00% | 1.00% | 1.00% | 1.00% |  | 1.00% |  |
Reporting unit, impairment test, estimated cash flows, discount rate | 9.00% |  |  | 10.00% | 10.00% | 9.00% |  | 10.00% |  |
Reporting unit, impairment test, estimated cash flows, change in discount rate |  |  |  | 1.00% | 1.00% |  |  | 1.00% |  |
Fair value of reporting value, greater than its carrying value | 10.00% |  |  |  |  | 2.00% |  |  |  |
Goodwill impairment | $ 0 |  | $ 469,000,000 |  | $ 83,000,000 | $ 0 |  |  |  |
Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Fair value of reporting value, greater than its carrying value |  |  |  | 25.00% | 25.00% |  |  | 25.00% |  |
Goodwill impairment |  |  |  | $ 0 |  |  |  |  |  |
All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Goodwill impairment |  |  |  |  | $ 0 |  |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rate |  | 2.00% | 1.00% |  |  |  | 2.00% |  | 2.00% |
Reporting unit, impairment test, estimated cash flows, discount rate |  | 7.00% | 11.00% |  |  |  | 7.00% |  | 7.00% |
Minimum | Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  | 9.00% |  |  |  |  |  |  |
Minimum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rate |  |  |  | 2.00% | 2.00% |  |  | 2.00% |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  | 9.00% | 9.00% |  |  | 9.00% |  |
Maximum |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rate |  | 3.00% | 3.00% |  |  |  | 3.00% |  | 3.00% |
Reporting unit, impairment test, estimated cash flows, discount rate |  | 10.00% | 12.25% |  |  |  | 10.00% |  | 10.00% |
Maximum | Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  | 10.00% |  |  |  |  |  |  |
Maximum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rate |  |  |  | 3.00% | 3.00% |  |  | 3.00% |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  | 11.50% | 11.50% |  |  | 11.50% |  |
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  | $ 88,000,000 |
Product brands |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  | $ 10,000,000 | 96,000,000 |
Finite-lived intangible assets |  |  |  | $ 4,112,000,000 | $ 4,112,000,000 |  |  | 4,112,000,000 |  | $ 4,673,000,000
Discontinued Product Lines |  |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  | $ 4,000,000 | $ 11,000,000 |

X
- Definition Annual Amortization Of Intangible Assets + References No definition available. + Details
Name: | bhc_AnnualAmortizationOfIntangibleAssets
Namespace Prefix: | bhc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Long-Term Growth Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestLongTermGrowthRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 55 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairedAccumulatedImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 55 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_GoodwillLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. + References No definition available. + Details
Name: | us-gaap_NumberOfReportingUnits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of fair value of reporting unit in excess of carrying amount. + References No definition available. + Details
Name: | us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |